The Cooper Companies, Inc. COO CooperSurgical — Research and development expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by The Cooper Companies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: The Cooper Companies, Inc.’s 10-Q, filed June 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Cooper Companies, Inc.'s coopersurgical — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Cooper Companies, Inc.'s coopersurgical — research and development expense?
- The Cooper Companies, Inc. (COO) reported coopersurgical — research and development expense of $20.4M in Q1 2026.
- How has The Cooper Companies, Inc.'s coopersurgical — research and development expense changed year-over-year?
- The Cooper Companies, Inc.'s coopersurgical — research and development expense increased by 2.5% year-over-year, from $19.9M to $20.4M.
- What does coopersurgical — research and development expense mean?
- Spending dedicated to creating new products and improving existing surgical technologies.
- How do you interpret coopersurgical — research and development expense?
- Higher spending indicates a commitment to long-term innovation, while lower spending may signal a focus on short-term profitability at the expense of future growth.
- How does coopersurgical — research and development expense compare across companies?
- Standard R&D expense metric common in life sciences and medical technology sectors.